恩夫韦地註射市场按患者类别、治疗线、剂型、给药途径和年龄组划分 - 全球预测 2026-2032

预计到 2025 年，恩夫韦地註射剂市场价值将达到 3.3851 亿美元，到 2026 年将成长至 3.6997 亿美元，到 2032 年将达到 6.3801 亿美元，复合年增长率为 9.47%。

关键市场统计数据
基准年 2025	3.3851亿美元
预计年份：2026年	3.6997亿美元
预测年份 2032	6.3801亿美元
复合年增长率 (%)	9.47%

本书精闢地介绍了注射用恩夫韦地在现代爱滋病治疗中的临床定位、操作复杂性以及相关人员的考量因素。

恩夫韦地是一种合成胜肽类抗逆转录病毒药物，主要透过注射给药，适用于对常规治疗方法产生抗药性的患者。其治疗特性、剂量复杂性和给药途径均与口服抗逆转录病毒不同，这影响临床医师、药师和医疗系统将其纳入治疗方案的方式。由于恩夫韦地是一种融合抑制剂，因此当需要一种作用机制不同的药物来优化治疗方案时，通常会考虑使用恩夫韦地。医疗专业人员会根据抗药性模式、依从性以及注射耐受性等因素来评估其适用性。

临床实践、供应链物流和患者治疗模式的重大变革正在重新定义注射型抗逆转录病毒药物的应用和治疗路径。

注射型抗逆转录病毒药物领域正经历显着的变革，这主要得益于临床创新、给药方式创新以及患者期望的不断变化。製剂科学的进步和给药装置的改进降低了给药难度，并扩大了注射疗法的应用范围。同时，严格的抗药性检测的广泛应用以及更完善的治疗流程的建立，也为恩夫韦地等药物开闢了新的临床应用领域，使其能够为因抗药性或不耐受而导致口服治疗选择有限的患者提供额外的价值。

近期贸易政策调整与关税相关压力如何推动注射剂治疗药物的供应链重组、筹资策略与韧性规划

美国近期关税政策的变化增加了注射用生物製药和胜肽类药物供应链计算的复杂性，影响了生产商和经销商的筹资策略和成本结构。针对活性药物成分、辅料和包装材料的关税提高了到岸成本，迫使生产商重新评估其采购基础，并优先选择贸易条件更有利地区的供应商。这一趋势正在推动近岸外包和供应来源多元化，以降低关税波动带来的风险，并确保关键注射疗法的持续供应。

详细的細項分析阐明了通路、患者特征、剂型和给药环境等因素，这些因素将影响恩氟韦地肽的策略发展。

细分市场洞察对于了解恩夫韦地在不同供应管道和患者群体中的应用至关重要。详细分析揭示了推动药物推广和取得的不同关键因素。考虑到分销管道的动态变化，诊所、医院和零售药局各自拥有不同的营运实践和决策标准。诊所分为综合诊所和专科诊所，其註射剂支持和患者教育资源水平各不相同。医院包括私立和公立机构，采购週期和预算框架也存在差异。零售药局分为连锁店和独立药局，其库存管理能力和医护人员协作能力也存在差异。这些差异为确定注射剂治疗的起始、维持和患者追踪的最佳环境提供了重要资讯。

美洲、欧洲、中东和非洲以及亚太地区在医疗服务取得、报销、监管路径和交付生态系统现状方面的区域观点

区域趋势对注射型抗逆转录病毒的可及性、报销框架、监管路径和临床实践模式均有显着影响。在美洲，医疗服务体系的特征是公共计画和私人支付者的多元化组合，这影响着采购週期和临床医生的奖励。价格谈判机制、报销核准以及专科诊所的可用性都会影响注射疗法的引入和持续使用。为了应对与注射疗法相关的依从性挑战，美洲的相关人员通常致力于将其与现有的门诊医疗基础设施整合，并制定患者支持计划。

从企业层面策略观点探讨注射疗法的製造合作、交付创新、临床证据倡议和生命週期管理方法。

公司层面的发展趋势反映了临床控制、生产规模和策略联盟之间的平衡。拥有成熟产品系列的创新公司具备深厚的临床数据、丰富的监管经验以及与医疗保健网络的紧密联繫，从而能够开展有针对性的教育活动和处方集；而中型製造商和专业公司则能够在包装创新、替代剂型以及灵活的供应安排方面展现出灵活性，以适应分散式医疗保健环境。在整个竞争格局中，临床研究团队、契约製造和分销专家之间的伙伴关係对于优化生产效率以及确保注射用肽类药物符合低温运输和无菌要求至关重要。

为製造商、医疗保健系统和支付方提供实用建议，以协调证据、商业策略和供应链韧性，从而支持注射型抗逆转录病毒的推广应用。

产业领导者应优先考虑整合临床证据产生、营运准备和支付方合作。首先，应投资于临床试验和真实世界研究，以验证特定潜在获益亚群（例如具有单一药物或多重抗药性特征的既往治疗患者）的治疗效果，并确保研究设计能够涵盖依从性和给药相关终点。其次，应优化产品剂型和包装，以方便在门诊和居家照护环境中使用。这包括提供看护者培训模组和标准化的低温运输管理通讯协定。

一份详尽的调查方法，阐述了资料来源、访谈架构、三角验证过程以及支撑分析的品管措施。

本研究采用多面向研究方法，结合了二手文献综述、相关人员咨询和迭代检验，以确保分析的严谨性。二手文献包括同侪审查的临床文献、监管申报文件和治疗指南，用于建立临床背景并验证作用机制、剂量特征和安全性考虑因素。一手研究包括对临床医生、药房主任、采购负责人和供应链专业人员进行结构化检验，以深入了解实际操作限制、剂量偏好和给药环境。

综合分析总结表明，需要协调临床证据、营运准备和支付方参与，才能有效实现注射疗法的可及性。

总之，我们强调，将临床效益与营运效用和支付方的认知相结合，对于恩夫韦地等注射剂的成功引入至关重要。抗药性管理和基于作用机制的临床差异化必须与满足培训需求、剂型偏好以及贯穿整个医疗服务链的给药环境的物流解决方案相协调。此外，供应链韧性与当地法规环境之间的策略互动将决定不同医疗体系中推广应用的速度和永续性。

目录

第一章：序言

第二章调查方法

• 研究设计
• 研究框架
• 市场规模预测
• 数据三角测量
• 调查结果
• 调查前提
• 调查限制

第三章执行摘要

• 首席体验长观点
• 市场规模和成长趋势
• 2025年市占率分析
• FPNV定位矩阵，2025
• 新的商机
• 下一代经营模式
• 产业蓝图

第四章 市场概览

• 产业生态系与价值链分析
• 波特五力分析
• PESTEL 分析
• 市场展望
• 市场进入策略

第五章 市场洞察

• 消费者洞察与终端用户观点
• 消费者体验基准
• 机会地图
• 分销通路分析
• 价格趋势分析
• 监理合规和标准框架
• ESG与永续性分析
• 中断和风险情景
• 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依病患类别分類的恩夫韦地註射液市场

• 接受过治疗的患者
  • 单药抗药性
  • 多重抗药性
• 未治疗的患者

9. 恩夫韦地註射液市场（依治疗系列划分）

• 后期治疗
• 二线治疗
• 三线治疗

第十章 恩夫韦地註射液市场（以剂型划分）

• 预填充式注射器
• 管瓶

第十一章 恩夫韦地註射液市场（依给药途径划分）

• 住院病人
• 门诊病人

第十二章 依年龄组别分類的恩夫韦地註射液市场

• 成人
• 儿童

第十三章 恩夫韦地註射液市场（按地区划分）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章 恩夫韦地註射液市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章 各国恩夫韦地註射液市场

• 我们
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

16. 美国恩夫韦地註射液市场

第十七章：中国恩夫韦地註射液市场

第十八章 竞争格局

• 市场集中度分析，2025年
  • 浓度比（CR）
  • 赫芬达尔-赫希曼指数 (HHI)
• 近期趋势及影响分析，2025 年
• 2025年产品系列分析
• 基准分析，2025 年
• AmbioPharm, Inc.
• Chengdu Shengnuo Biopharm Co., Ltd
• CordenPharma International GmbH
• Didu Group Co., Ltd.
• Genentech, Inc.
• Hangzhou Go Top Peptide Biotech Co., Ltd.
• JYMed Technology Co., Ltd.
• NJPeptide, Inc.
• Roche Holding AG
• Trimeris
• ZPC Biotechnology Co., Ltd.

The Enfuvirtide for Injection Market was valued at USD 338.51 million in 2025 and is projected to grow to USD 369.97 million in 2026, with a CAGR of 9.47%, reaching USD 638.01 million by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 338.51 million
Estimated Year [2026]	USD 369.97 million
Forecast Year [2032]	USD 638.01 million
CAGR (%)	9.47%

An incisive introduction to the clinical positioning operational complexities and stakeholder considerations shaping the use of injectable enfuvirtide in contemporary HIV care

Enfuvirtide is a synthetic peptide antiretroviral administered by injection, positioned predominantly for patients who have encountered resistance to conventional regimens. The therapeutic profile, dosing complexity, and administration route distinguish it from oral antiretroviral agents and shape how clinicians, pharmacists, and healthcare systems incorporate it into treatment pathways. Given its role as a fusion inhibitor, enfuvirtide is often considered when regimen optimization requires agents with a distinct mechanism of action, and practitioners evaluate its suitability within the context of resistance patterns, adherence considerations, and injection-related tolerability.

Clinical adoption of enfuvirtide is influenced by a range of practical factors that extend beyond efficacy alone. Injection training, cold chain logistics, and choices between prefilled syringes or vials are operational determinants that affect clinician preference and patient acceptance. Moreover, the drug's positioning within therapy lines and its utility for treatment-experienced patients with specific resistance profiles create a clinical niche that necessitates targeted educational outreach and clear guidelines. As a result, stakeholders across care settings must align on protocols for initiation, monitoring, and patient support to realize therapeutic benefit while minimizing barriers to use.

Key transformative shifts in clinical practice supply chain logistics and patient delivery models that are redefining injectable antiretroviral adoption and care pathways

The landscape for injectable antiretrovirals has undergone meaningful shifts driven by clinical innovation, delivery innovations, and evolving patient expectations. Advances in formulation science and improvements in delivery devices have reduced administration friction and expanded the contexts in which injectable therapies can be offered. Concurrently, the rise of precision resistance testing and more nuanced treatment algorithms has clarified the clinical niches where agents such as enfuvirtide deliver incremental value, particularly for patients with limited oral options due to resistance or intolerance.

Operational shifts are equally consequential. Health systems have reconfigured outpatient services and home care pathways to accommodate injectable therapies, integrating nurse-led programs, patient training modules, and remote adherence monitoring. Commercial dynamics have adjusted to this new paradigm as manufacturers and distributors refine packaging formats and supply logistics to better support clinics, hospitals, and home-based administration. As a result, the cumulative effect is a more flexible adoption environment where clinical utility, ease of administration, and integrated care models interact to reshape how injectable antiretrovirals are deployed.

How recent trade policy adjustments and tariff-related pressures are catalyzing supply chain redesign procurement strategies and resilience planning for injectable therapeutics

Recent tariff activity in the United States has added complexity to the supply chain calculus for injectable biologics and peptide therapeutics, affecting procurement strategies and cost structures for manufacturers and distributors. Tariff measures that target active pharmaceutical ingredients, excipients, or packaging components can increase landed costs, prompting manufacturers to reassess sourcing footprints and to prioritize suppliers in jurisdictions with more favorable trade terms. In turn, this dynamic encourages nearshoring and diversification of supply to mitigate exposure to tariff volatility and to preserve continuity of supply for critical injectable therapies.

Healthcare providers and procurement teams have responded by increasing emphasis on contractual flexibility and by seeking longer-term supply agreements that hedge against abrupt cost shifts. Payers and hospital systems are scrutinizing total cost of care implications, including the downstream effects of administration setting changes and the potential need for additional support services when therapy affordability is affected. Additionally, regulatory and customs processes have become more salient as logistics teams prioritize compliance and documentation to avoid clearance delays. Overall, tariffs are acting as a catalyst for strategic supply chain redesign rather than as an isolated cost pressure, accelerating a shift toward more resilient sourcing, enhanced inventory governance, and closer collaboration between manufacturers and downstream partners.

Deep segmentation insights explaining how distribution channels patient profiles dosage formats and administration settings influence the strategic deployment of enfuvirtide

Segmentation-driven insight is central to understanding how enfuvirtide will be utilized across delivery channels and patient cohorts, and a granular view reveals differentiated levers for adoption and access. When distribution channel dynamics are considered, clinics, hospitals, and retail pharmacies each present distinct operational realities and decision criteria; clinics span general and specialty clinics with varying levels of injection support and patient education resources, hospitals include private and public institutions with divergent procurement cycles and budgetary frameworks, and retail pharmacies encompass chain and independent outlets that differ in their capacity to manage storage and clinician coordination. These differences inform which settings are best suited for initiation, maintenance, and patient follow-up for an injectable agent.

Patient category segmentation highlights the clinical imperative: treatment experienced and treatment naive populations present different therapeutic rationales, with treatment experienced patients further characterized by mono-resistant and multi-drug resistant profiles, which directly influence regimen selection and the perceived value of a fusion inhibitor. Age group segmentation underscores both clinical and adherence considerations, as adult and pediatric cohorts have distinct dosing, counseling, and support needs; adults are further segmented into general adult and senior populations where comorbidity burden and polypharmacy matter, while pediatric patients encompass adolescent, child, and neonatal subgroups that require tailored administration approaches and caregiver support. Therapy line segmentation clarifies placement across later line, second line, and third line use, and the later line classification subdivides into fourth line and fifth line and beyond scenarios where clinical necessity and limited alternatives drive usage. Dosage form and administration setting complete the picture: prefilled syringes versus vials, including 180 mg and 90 mg vial formats, and inpatient versus outpatient administration settings, with inpatient care spanning general ward and intensive care unit contexts and outpatient care covering ambulatory clinics and home care, all shape logistics, training needs, and patient experience. Integrating these segmentation lenses allows stakeholders to identify high-priority use cases, tailor educational programs, and design distribution strategies that align with the operational capacities and clinical requirements of each segment.

Regional perspectives on access reimbursement regulatory pathways and delivery ecosystem realities across the Americas Europe Middle East Africa and Asia-Pacific

Regional dynamics exert a pronounced influence on access, reimbursement frameworks, regulatory pathways, and clinical practice patterns for injectable antiretrovirals. In the Americas, healthcare delivery is characterized by a diverse mix of public programs and private payers, which shapes procurement cycles and clinician incentives; pricing negotiation mechanisms, reimbursement approvals, and the presence of specialized clinics drive how injectable therapies are introduced and sustained. Stakeholders in the Americas frequently focus on integration with established outpatient infrastructure and the development of patient support programs to address adherence challenges associated with injection therapies.

In Europe, Middle East & Africa, heterogeneity across national health systems influences adoption timelines and the complexity of regulatory approvals, with some markets emphasizing centralized procurement and others operating through decentralized hospital budgets; this creates varying pathways for formulary inclusion and clinician adoption. Capacity constraints in certain regions necessitate tailored training and creative delivery models, including expansion of ambulatory care and task shifting to allied health personnel where appropriate. The Asia-Pacific region exhibits a wide spectrum of public and private healthcare arrangements, regulatory environments, and manufacturing capabilities. Robust domestic pharmaceutical manufacturing in several countries supports regional supply resilience, while disparities in healthcare infrastructure mean that home-based care and ambulatory clinic networks can be pivotal in enabling access. Across regions, cross-border trade dynamics, intellectual property frameworks, and local clinical guidelines shape how injectable antiretrovirals are evaluated and adopted, requiring manufacturers and providers to pursue regionally nuanced strategies that reflect local payer priorities, clinician workflows, and patient support needs.

Strategic company level perspectives on manufacturing collaborations delivery innovations clinical evidence initiatives and lifecycle management approaches for injectable therapies

Company-level dynamics reflect a balance between clinical stewardship, manufacturing scale, and strategic collaboration. Innovator organizations with established portfolios bring depth in clinical data, regulatory experience, and relationships with care networks, enabling targeted education and formulary engagement. At the same time, mid-sized manufacturers and specialty firms can provide agility in packaging innovation, alternate dosage forms, and flexible supply arrangements that appeal to decentralized care settings. Across the competitive landscape, partnerships between clinical research groups, contract manufacturing organizations, and distribution specialists are instrumental in optimizing production throughput and ensuring compliance with cold chain and sterility requirements for injectable peptides.

Intellectual property and lifecycle management strategies influence investment in next-generation delivery technologies, such as improved syringe designs and alternative vial configurations that simplify administration and reduce wastage. Companies are also investing in real-world evidence initiatives to demonstrate practical benefits in adherence and resistance management, and they are exploring collaborations with healthcare systems to pilot clinic-based and home-administration programs. These corporate actions are central to differentiating offerings and to building the trust required for clinicians and payers to incorporate an injectable agent into complex treatment regimens.

Actionable recommendations for manufacturers healthcare systems and payers to align evidence commercial strategy and supply chain resilience in support of injectable antiretroviral adoption

Industry leaders should prioritize integrated approaches that align clinical evidence generation with operational readiness and payer engagement. First, invest in clinical and real-world studies that document outcomes for the specific subgroups most likely to benefit, including treatment experienced patients with mono-resistant and multi-drug resistant profiles, and ensure that study designs capture adherence and administration-related endpoints. Second, optimize product formats and packaging to support ease of use in both ambulatory and home-care environments, including training modules for caregivers and standardized protocols for cold chain management.

Third, proactively engage payers and hospital procurement teams to clarify the clinical value proposition and to co-design pathways that minimize administrative friction at initiation. Fourth, reconfigure supply chains to enhance resilience against tariff and trade disruptions by diversifying component sourcing and considering selective nearshoring for critical inputs. Fifth, foster partnerships with nursing networks and specialty clinics to scale injection training and patient support services, thereby reducing barriers at the point of care. By executing on these priorities, companies and healthcare organizations can accelerate clinically appropriate adoption while aligning operational capabilities with patient needs.

Comprehensive research methodology detailing data sources interview frameworks triangulation processes and quality control measures underpinning the analysis

The study relies on a multi-method research approach that combines secondary literature review with stakeholder consultations and iterative validation to ensure analytical rigor. Secondary sources included peer-reviewed clinical literature, regulatory filings, and treatment guidelines to establish the clinical context and to verify mechanism of action, dosing characteristics, and safety considerations. Primary research involved structured interviews with clinicians, pharmacy directors, procurement officers, and supply chain specialists to capture real-world operational constraints, preferences for dosage forms, and views on administration settings.

Data triangulation was performed by cross-referencing interview findings with published clinical guidance and product labeling, and by validating logistical observations against distribution and cold chain best practices. Limitations were acknowledged, including variability in regional practice patterns and the evolving nature of resistance testing and treatment algorithms. To mitigate these, sensitivity checks were applied and methodological assumptions were documented to maintain transparency. Quality control included expert review panels and internal consistency checks to ensure that conclusions reflect robust synthesis rather than isolated perspectives.

Concluding synthesis emphasizing the necessity of aligning clinical evidence operational readiness and payer engagement to enable effective access for injectable therapeutics

The concluding synthesis highlights that successful deployment of an injectable agent such as enfuvirtide depends on aligning clinical utility with operational practicability and payer recognition. Clinical differentiation rooted in resistance management and mechanism of action must be matched by logistical solutions that address training needs, dosage format preferences, and administration settings across care continua. Moreover, the strategic interplay between supply chain resilience and regional regulatory environments will determine the speed and sustainability of adoption across diverse healthcare systems.

Ultimately, stakeholders that integrate targeted evidence generation, adaptable packaging and delivery models, and collaborative payer engagement are best positioned to overcome the unique challenges associated with injectable therapies. This holistic approach ensures that clinical value is accessible in the settings where it is most needed while maintaining the operational agility required to respond to trade and procurement dynamics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enfuvirtide for Injection Market, by Patient Category

• 8.1. Treatment Experienced
  • 8.1.1. Mono-Resistant
  • 8.1.2. Multi-Drug Resistant
• 8.2. Treatment Naive

9. Enfuvirtide for Injection Market, by Therapy Line

• 9.1. Later Line
• 9.2. Second Line
• 9.3. Third Line

10. Enfuvirtide for Injection Market, by Dosage Form

• 10.1. Prefilled Syringes
• 10.2. Vials

11. Enfuvirtide for Injection Market, by Administration Setting

• 11.1. Inpatient
• 11.2. Outpatient

12. Enfuvirtide for Injection Market, by Age Group

• 12.1. Adult
• 12.2. Pediatric

13. Enfuvirtide for Injection Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Enfuvirtide for Injection Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Enfuvirtide for Injection Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. United States Enfuvirtide for Injection Market

17. China Enfuvirtide for Injection Market

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025
• 18.5. AmbioPharm, Inc.
• 18.6. Chengdu Shengnuo Biopharm Co., Ltd
• 18.7. CordenPharma International GmbH
• 18.8. Didu Group Co., Ltd.
• 18.9. Genentech, Inc.
• 18.10. Hangzhou Go Top Peptide Biotech Co., Ltd.
• 18.11. JYMed Technology Co., Ltd.
• 18.12. NJPeptide, Inc.
• 18.13. Roche Holding AG
• 18.14. Trimeris
• 18.15. ZPC Biotechnology Co., Ltd.

LIST OF FIGURES

• FIGURE 1. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 12. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 13. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MONO-RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY MULTI-DRUG RESISTANT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT NAIVE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY LATER LINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 48. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 49. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 50. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 51. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 52. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 53. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 54. AMERICAS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 55. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 56. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 57. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 58. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 59. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 60. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 61. NORTH AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 62. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 63. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 64. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 65. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 66. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 67. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 68. LATIN AMERICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 69. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 70. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 71. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 72. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 73. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 74. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 75. EUROPE, MIDDLE EAST & AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 76. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 77. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 78. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 79. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 80. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 81. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 82. EUROPE ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 83. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 84. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 85. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 86. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 87. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 88. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 89. MIDDLE EAST ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 90. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 92. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 93. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 94. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 95. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 96. AFRICA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 97. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 99. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 100. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 101. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 102. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 103. ASIA-PACIFIC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 105. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 106. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 107. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 108. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 109. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 110. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 111. ASEAN ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 112. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 113. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 114. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 115. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 116. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 117. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 118. GCC ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 119. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 120. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 121. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 122. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 123. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 124. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 125. EUROPEAN UNION ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 126. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 127. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 128. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 129. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 130. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 131. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 132. BRICS ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 133. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 134. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 135. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 136. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 137. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 138. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 139. G7 ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 140. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 141. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 142. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 143. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 144. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 145. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 146. NATO ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 147. GLOBAL ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 148. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 149. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 150. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 151. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 152. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 153. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 154. UNITED STATES ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
• TABLE 155. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 156. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY PATIENT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 157. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY TREATMENT EXPERIENCED, 2018-2032 (USD MILLION)
• TABLE 158. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
• TABLE 159. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
• TABLE 160. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY ADMINISTRATION SETTING, 2018-2032 (USD MILLION)
• TABLE 161. CHINA ENFUVIRTIDE FOR INJECTION MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)